Merck (NYSE:MRK) said today that the FDA granted tentative approval for its Lusduna Nexvue insulin glargine injection.
The biologic basal insulin met regulatory standards, the company said, but a patent infringement lawsuit initiated by competitor Sanofi (NYSE:SNY) in September of last year invoked an automatic delay for the drug-device combination product’s final approval.
Get the full story at our sister site, Drug Delivery Business News.
The post Lawsuit stalls approval of Merck’s insulin injection appeared first on MassDevice.